The total number of records retrieved from this search are 20. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
OV_487	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	1 MOI	102% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_491	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	5 MOI	98% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_495	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	10 MOI	96% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_499	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	50 MOI	80% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_503	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	100 MOI	56% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_507	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	1 MOI	99% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_511	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	5 MOI	84% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_515	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	10 MOI	65% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_519	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	50 MOI	50% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_523	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	100 MOI	36% cancer cell viability (calculated as relative to mock-infected group), antagonist effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_527	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	1 MOI	83% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_531	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	5 MOI	77% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_535	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	10 MOI	60% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_539	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	50 MOI	45% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_543	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	100 MOI	35% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_547	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	1 MOI	65% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_551	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	5 MOI	60% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_555	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	10 MOI	50% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_559	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	50 MOI	38% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_563	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	DS Pharma Biomedical	Human osteosarcoma cell line	MNNG/HOS	1.0E+3 cells per well	NA	XTT assay	100 MOI	25% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624